symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
ATXI,0.601,-0.261666,69904,5387496,0,0.539-4.24,-0.0041,"Avenue Therapeutics, Inc.",USD,0001644963,US05360L2051,05360L205,NASDAQ Capital Market,NASDAQ,Biotechnology,https://www.avenuetx.com,"Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was incorporated in 2015 and is based in New York, New York.",Dr. Alexandra  MacLean M.D.,Healthcare,US,2,781 652 4500,1140 Avenue of the America,New York,NY,10036,0.0802278,1.46023,https://financialmodelingprep.com/image-stock/ATXI.png,2017-06-27,False,False,True,False,False
